X

Trial Profile

Factor XA - Inhibition in RENal Patients With Non-valvular Atrial Fibrillation - Observational Registry

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 10 Apr 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Rivaroxaban (Primary) ; Vitamin K antagonists
Indications Cardiovascular disorders; Stroke; Thromboembolism
Focus Adverse reactions; Therapeutic Use
Acronyms XARENO

Most Recent Events

06 Mar 2023 According to a Bayer media release, final data from this study were presented at the American Congress of Cardiologys 72nd Annual Scientific Session together with World Congress of Cardiology (ACC.23/WCC).
06 Mar 2023 Results presented in the Bayer Media Release
18 Jul 2022 Status changed from active, no longer recruiting to completed.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com